Bank of Montreal
PRTK

Bank of Montreal’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Bank of Montreal’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-900
Closed -$4K – 5061
2019
Q3 		$4K Buy
+900
New +$3.6K ﹤0.01% 4589

Other funds holding PRTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of Montreal's PRTK Position: Q2 2021 in Review

Bank of Montreal sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2021, closing a stake of 2,692 shares — an estimated $18K sold.

Bank of Montreal first reported a position in PRTK in Q1 2017 and held it in 17 quarters. The position peaked at $136K in Q1 2018. 116 funds tracked by Wall St. Rank hold PRTK as of Q2 2021.

  • Bank of Montreal reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Bank of Montreal sold 2,692 Paratek Pharmaceuticals, Inc. shares in Q2 2021, an estimated $18K.
  • Bank of Montreal first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2017 and held it in 17 quarters.
  • Bank of Montreal's Paratek Pharmaceuticals, Inc. position peaked at $136K in Q1 2018.
  • 116 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2021.

Based on Bank of Montreal's 13F filing for Q2 2021, filed 12 Aug 2021.